The addition of tafasitamab-cxix to lenalidomide and rituximab has shown to improve outcomes for patients suffering from relapsed or refractory follicular lymphoma. Tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, is already approved in the United States for treating adults with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant.
The phase 3 inMIND trial involved 654 adults with relapsed or refractory follicular lymphoma or marginal zone lymphoma, focusing on PFS as the primary endpoint. The trial successfully met its primary and key secondary endpoints, indicating significant improvement in PFS among the treated patients. Additionally, the study reported no new safety signals, with the most common adverse events being fatigue or weakness, cough, fever, diarrhea, respiratory tract infection, swelling of the hands or lower legs, and decreased appetite.
Incyte, the manufacturer of tafasitamab-cxix, anticipates submitting a supplemental biologics license application by the end of the year for the treatment of follicular lymphoma patients who have failed at least one previous systemic anti-CD20 immunotherapy or chemoimmunotherapy.
